Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J's Palmaz-Schatz stent

This article was originally published in The Gray Sheet

Executive Summary

Six-month follow-up of a randomized trial comparing the Johnson & Johnson Heparin coated stent with balloon angioplasty in patients with acute myocardial infarction shows a 12.4% risk of death, repeat MI, disabling cerebrovascular accident and ischemia-driven target vessel revascularization in the stent arm compared to 20.1% in the angioplasty arm (p<0.01), the study's primary endpoint. Results from the 62-center, 900 patient trial were presented at an AHA press conference Nov. 9 by Cindy Grines, MD, William Beaumont Hospital, Royal Oak, Michigan. The results also show reduced restenosis in the stent arm (20.3% vs. 32.5%; p<0.001) and reduced angina (11.1% vs. 16.9%; p<0.02). Six-month reocclusion rates were also favorable compared to PTCA (10-13%) and thromobolytic therapy (30%), Grines noted. "In the era of stenting it looks like we've reduced that down to 4%, that's a major improvement and could potentially reduce rates of reinfarction" and improve LV function, Grines said

You may also be interested in...

ASTM Developing Standard To Tackle Dried Blood On Steel Devices

ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir

The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts